Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced data demonstrating the ability to detect the EML4-ALK mutation and specific associated RNA fusion transcripts in blood plasma of patients with non-small cell lung cancer (NSCLC). The data were presented at a poster session yesterday, Sunday, April 19, 2015, titled, “Plasma-based diagnostics for detection of EML4-ALK fusion transcripts in NSCLC patients,” at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, Pa.